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Abstract
Background:  Medication nonadherence can be as high as 50% and results in suboptimal patient
outcomes. Stroke patients in particular can benefit from pharmacotherapy for thrombosis, hypertension,
and dyslipidemia but are at high risk for medication nonpersistence.
Methods: Patients who were admitted to the Queen Elizabeth II Health Sciences Centre in Halifax, Nova
Scotia, with stroke between January 1, 2001 and December 31, 2002 were analyzed. Data collected were
pre-stroke function, stroke subtype, stroke severity, patient outcomes, and medication use at discharge,
and six and 12 months post discharge. Medication persistence at six and 12 months and the factors
associated with nonpersistence at six months were examined using multivariable stepwise logistic
regression.
Results: At discharge, 420 patients (mean age 68.2 years, 55.7% male) were prescribed an average of 6.4
medications and mean prescription drug cost was $167 monthly. Antihypertensive (91%) and
antithrombotic (96%) drug use at discharge were frequent, antilipidemic (73%) and antihyperglycemic
(25%) drug use were less common. Self-reported persistence at six and 12 months after stroke was high
(> 90%) for all categories.
In the multivariable model of medication nonpersistence at six months, people aged 65 to 79 years were
less likely to be nonpersistent with antihypertensive medications than people aged 80 years or more (Odds
ratio (OR) 0.11, 95% Confidence Interval (CI) 0.03–0.39). Monthly drug costs of < $90 or $90–199.99
were associated with greater nonpersistence, compared to monthly drug costs ≥$200 (OR 6.74, 95% CI
1.32–34.46 for < $90; OR 5.25, 95% CI 1.14–24.25 for $90–199.99). For the antithrombotic drug category,
people aged 65 to 79 years were less likely to be nonpersistent than people aged 80 years or more (OR
0.23, 95% CI 0.06–0.81), and people who were disabled before admission were more likely to be
nonpersistent than those not disabled (OR 7.01, 95% CI 1.66–29.58).
Conclusion:  Patients reported high medication persistence rates six and 12 months after stroke.
Identification of factors associated with nonpersistence (such as older age and prior disability) will help
predict which patients are at higher risk for discontinuing their medications.
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Background
Stroke is the third leading cause of death worldwide,
responsible for 10% of all deaths.[1] Every year, 15 mil-
lion people will have a stroke, of whom five million will
die, and another five million will be permanently disa-
bled. In North America, just over 15,000 people in Can-
ada and 160,000 in the United States, died in 2000 from
a stroke. Total costs for stroke, such as medical care and
lost productivity, were estimated to be US $53.6 billion in
2000 for the United States.[1]
Persons recovering from a stroke or transient ischemic
attack (TIA) are at high risk for recurrent stroke, disability,
institutionalization, and death.[2] Pharmacotherapy that
targets hypertension, vascular disease, and hyperlipi-
demia can decrease the risk of further vascular events and
mortality.[2] Risk factor management in stroke patients
has been the subject of numerous randomized clinical tri-
als and meta-analyses of these trials. [2-13] These studies
have shown that for people with atrial fibrillation and pre-
vious TIA, anticoagulant use can reduce recurrent stroke
by two-thirds, and all vascular events can be reduced by
one-half.[6] For patients with stroke in normal sinus
rhythm, antiplatelet agents (such as acetylsalicylic acid,
ASA) decrease the relative risk of stroke by 24%.[7] A 22%
overall odds reduction of serious vascular events (non-
fatal myocardial infarction [MI], non-fatal stroke, or vas-
cular death) has also been attributed to antiplatelet ther-
apy.[8] Blood pressure (BP) reduction for secondary
prevention can reduce the relative risk of stroke by 22%
for a 10 mmHg systolic BP reduction.[9] Results are simi-
lar regardless of the type of medication used.[9] Statins (a
family of lipid-lowering agents such as atorvastatin and
simvastatin) have been shown to produce an approximate
25% relative risk reduction of stroke in patients with a his-
tory of stroke or TIA.[10,11]
Despite the proven efficacy, medication nonadherence for
patients with chronic diseases can be as high as 50% and
is the main reason why patients do not achieve maximum
clinical benefit.[14] Medication persistence, or continuing
to take a medication long-term, is one aspect of medica-
tion adherence. Stroke patients are potentially at high risk
for medication nonpersistence because they require long-
term drug therapy, are more likely to have cognitive or
physical impairments, and are often depressed.[15] A
recent study investigated persistence of lipid lowering
therapies after stroke and found that 39% of patients had
discontinued therapy at one year after discharge.[16].
Medication persistence rates after stroke have varied from
37–96%, depending on the medication, in the small
number of studies that have examined this issue. [16-21]
One study that analyzed patient variables associated with
medication use found that older age and a cardioembolic
cause of stroke were significantly predictive of higher
medication compliance.[19]
It is unclear how well patients persist in taking their med-
ications at one year after discharge from a Canadian acute
stroke unit. As well, understanding potential factors that
may affect persistence can assist health providers in sup-
porting those patients at risk of stopping their medica-
tions. Our objectives were to report medication
persistence rates for four important drug categories at six
and 12 months after stroke, and analyze the potential
demographic and clinical factors associated with medica-
tion persistence at six months.
Methods
The study population were stroke patients prospectively
enrolled in the Stroke Outcome Study (SOS) at the Acute
Stroke Unit (ASU) of the Queen Elizabeth II Health Sci-
ences Centre (QEII HSC) between January 1, 2001 and
December 31, 2002 and followed for one year. The QEII
HSC is a 1000 bed, tertiary care and referral centre for the
Canadian Atlantic provinces. The ASU treats 25% of all
patients who have a stroke in Nova Scotia. The acute
stroke team includes neurologists, nurses, dieticians, and
physiotherapists who are trained in acute stroke manage-
ment. A pharmacist provides pharmaceutical care as part
of the healthcare team and conducts follow-up visits in
the stroke clinic which focus on medication management
and compliance. Medical treatment is standardized by
using preprinted order sets and preprinted interim dis-
charge reports for family physicians. A description of the
care received and patient outcomes has been pub-
lished.[22]
The SOS data collection occurred during hospitalization,
six months, and 12 months after stroke. Data collected
during the hospitalization included demographics (age,
sex, marital status, postal code), preadmission disability
(Oxford Handicap Score [OHS][23], previous history of
stroke, mortality, stroke recurrence, length of stay, stroke
subtype (Oxford Community Stroke Project [OCSP] sub-
types[24]), stroke severity (First Stroke Severity Score
[FSSS][25]), functional status (Oxford Handicap Score
and Barthel Index[26]), cognitive status (clock draw-
ing[26] and orientation to person, place, time[27]), dis-
charge medication list and discharge disposition
(discharged home, to a long term care facility, etc.). Age
was categorized into < 65 years old, 65–79 years old, and
80 years and greater. The OHS functional disability score
was categorized into dependent on others for activities of
daily living (score 4–5) or independent (score 0–3).
OCSP stroke subtypes for ischemic stroke were defined as
lacunar stroke (LACS), partial anterior circulation stroke
(PACS), posterior circulation stroke (POCS), total ante-
rior circulation stroke (TACS), transient ischemic attackBMC Neurology 2008, 8:25 http://www.biomedcentral.com/1471-2377/8/25
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(TIA) or uncertain. Stroke severity was defined as a FSSS
score of mild (score 1–4), moderate (score 5–7), severe
(score 8–10), or TIA (score 11). Cognitive impairment,
measured by the clock drawing test during the patient's
hospitalization, was also converted into a dichotomous
variable where a score of ≤ 12 meant impairment, and
scores > 12 meant normal cognitive functioning. Medica-
tion use before admission to the hospital was not
recorded.
Data collected at six months were mortality, stroke recur-
rence, disposition, functional status (modified Rankin
scale [MRS][28] and Barthel Index), and self-reported
medication use. The MRS functional disability score was
categorized into dependent on others for activities of daily
living (score 4–5) or independent (score 0–3). Medica-
tion use was collected by the study coordinator who made
all attempts to be as complete as possible by asking for
help from caregivers, asking the names to be read from
medication bottles or brought in to the study visit, obtain-
ing medication lists from nursing homes, and calling
pharmacies for verification if there was any doubt in the
accuracy of the list. Data collected at 12 months were mor-
tality, stroke recurrence, disposition, functional status
(MRS and Barthel Index), cognitive status (clock drawing
and orientation to person, place, time), depression score
(Geriatric Depression Scale[29]), dementia score (Global
Deterioration Scale[30]), and self-reported medication
use. However, not all variables were needed for the medi-
cation persistence sub-study reported here.
The SOS Study did not collect any clinical information
such as blood pressure measurements, lipid profile tests,
health resource use, or lifestyle modifications after the
stroke which could include exercise, smoking cessation, or
diet changes. Medication use was recorded but reasons
why the drug regimen changed, such as due to adverse
effects, were not obtained from patients or their family
practitioners. As well, how much patients paid for their
medications out of pocket was not obtainable for this
study.
Inclusion criteria for the medication persistence sub-study
were:
￿ Diagnosed ischemic stroke – stroke type was determined
by the attending neurologist after thorough neurological
exam and CT scan to rule out hemorrhagic stroke or
tumor,
￿ Survived the hospitalization,
￿ Medication list available at discharge and six months,
and
￿ Completed the 12 month visit or had died by 12
months.
Ethics approval was received from the Capital Health
Research Ethics Board on January 13, 2005 and the study
was conducted according to institutional guidelines.
Additional variables
Variables needed for the medication persistence sub-study
were then added to the SOS dataset. Medication use had
been recorded on paper so medication names, dose and
directions at discharge, six months, and 12 months were
then entered into a Microsoft Excel spreadsheet (Version
11.0, Microsoft® Office Excel 2003, Redmond, Washing-
ton, US). Medications were coded according to the 2004
World Health Organization's (WHO) Anatomical Thera-
peutic Chemical (ATC) System, which categorizes phar-
maceuticals according to the organ or system on which
they exert their effect and their specific chemical proper-
ties.[31] All antihyperglycemic (group A10), antithrom-
botic (B01), antihypertensive (C02 – C09) and
antilipidemic (C10) medications were coded at discharge,
six months, and 12 months for each patient.[31]
Monthly drug costs for prescription drugs, excluding phar-
macists' professional fees, were estimated from the
patient's discharge medication list. Prices were obtained
from the January 2005 Atlantic Pharmaceutical Services
Incorporated (APSI) Pricing Guide[32] (2617 drugs or
99.3%), from PPS Pharma 2002[33] (two drugs), PPS
Pharma 2000[34] (three drugs) and the hospital phar-
macy price (13 drugs). Costs were conservatively esti-
mated by using the lowest price per unit (brand or if off-
patent the lowest generic price). Missing directions were
obtained from the hospital computer system (78 drugs)
or by using the WHO Defined Daily Dose (DDD)[31] (20
drugs). The WHO defines the DDD as "the assumed aver-
age maintenance dose per day for a drug used for its main
indication in adults".[31] If a reported dose appeared to
be an outlier (greater than twice the upper limit or less
than half of the lower limit of Health Canada's approved
dose), the WHO DDD was used to estimate the cost (one
drug). Antibiotics were costed for five days duration only.
Drug costs were then categorized into three groups: < $90/
month, $91–199.99/month, or $200 or greater/month.
Patients were considered to have diabetes or atrial fibrilla-
tion if the diagnosis was coded from the hospital's health
records data as a co-morbidity or secondary diagnosis dur-
ing the hospitalization for stroke. The International Clas-
sification of Diseases diagnosis codes for diabetes were
250 (9th version) and E10, E11, or E14 (10th version). The
codes for atrial fibrillation were 427.3 (9th version) and
I48 (10th version).[35] Diabetes could be treated with
pharmacological agents or diet controlled. The actual dateBMC Neurology 2008, 8:25 http://www.biomedcentral.com/1471-2377/8/25
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of diagnosis for the comorbidity was not available.
Tobacco use at the time of admission was obtained from
the hospital discharge report. The Population Health
Research Unit at Dalhousie University, Halifax, Nova Sco-
tia[36] provided average household income by linking the
patients' postal codes to 2001 Canadian Census data.
Average household income was unavailable for 22
patients (5.4%) residing in a geographic area with a pop-
ulation of less than 250. The number of non-research
related visits to the QEII HSC Neurology clinic between
the patient's discharge and 12 month visit were docu-
mented from the hospital pharmacy computer system.
Study outcome
The outcome measure was medication persistence for the
antihypertensive, antithrombotic, antilipidemic, and anti-
hyperglycemic drug categories. Patients were classified as
persistent or nonpersistent at six months by comparing
the discharge medication list with the six month medica-
tion list. Patients were classified as persistent or nonper-
sistent at 12 months by comparing the discharge
medication list with the 12 month medication list, if it
was available. Since patients derive benefit if they con-
tinue taking any drug within the drug category of interest
(eg. antihypertensive), we considered patients to be per-
sistent for the drug category, not for the individual drugs.
Patients who switched from one drug to another were
considered persistent for the purposes of this study. This
method will provide high estimates of persistence but will
reflect a better "real-world" analysis of whether patients
continue to take their medication after stroke.
Statistical methods
The multidimensional WHO model of factors that affect
medication adherence were utilized as a guide to analyze
medication persistence.[14] Logistic regression was used
to test variables for univariate associations with medica-
tion persistence. The following variables were tested in
each drug category: age, sex, marital status, household
income, tobacco use, number of medications or doses
taken daily, medication costs, previous stroke history,
atrial fibrillation, diabetes, stroke subtype, stroke severity,
functional disability, and cognitive status during hospital-
ization. Variables associated at the 10% level of signifi-
cance were entered in a multivariable stepwise logistic
regression model. Effect modifiers were identified using
the Breslow-Day test for homogeneity of the odds ratio,
with p < 0.05 indicating the existence of effect modifica-
tion. If this occurred, the regression model was stratified
by the effect modifier. All analyses were performed using
SAS software (version 8.02, SAS® Institute, Cary, North
Carolina, US).
Results
Demographics
There were 671 patients admitted with stroke to the ASU
between January 1, 2001 and December 31, 2002, of
whom 618 (92%) gave informed consent for the study. Of
these, 198 patients were excluded due to hemorrhagic
stroke (71), death between hospital admission and the six
month visit (105), missing medication list (10) and loss
to follow-up (12) (Figure 1). This left 420 patients availa-
ble for analysis for medication persistence at the six
month visit (Table 1). At 12 months, a further 18 patients
were not eligible (17 had died and 1 was missing a medi-
cation list), leaving 402 patients available at the last visit.
The mean age was 68.2 years (standard deviation 13.8)
and 234 (55.7%) were male. There were 145 patients
(34.5%) who returned for follow-up to the neurology
clinic in the first year after discharge. These follow-up vis-
its were part of standard care and not required by the
research study. Half of the patients did not have cognitive
testing performed (53.6%) either because the patient was
not able to perform the test (eg. very severe illness) or the
patient was discharged before the test could be adminis-
tered (eg. very mild illness).
Medication use and persistence
At discharge, six and 12 months, approximately 25% of
the cohort reported the use of an antihyperglycemic
(Table 2). Frequency of use in the antihypertensive cate-
gory ranged from 91% at discharge to 88% at 12 months.
Antithrombotic use was above 90% at each time point (or
96%, 93%, and 94%, at discharge, six and 12 months).
Fewer patients were prescribed antilipidemic agents (72–
75%).
Medication persistence was calculated for the patients
who were prescribed the drug at discharge, and was high
in all four drug categories at the six and 12 month time
points (Table 2). Persistence was highest for the antihy-
perglycemic drug category (97%) and lowest for the antil-
ipidemics (91%) at one year. Within the antithrombotic
category, anticoagulant persistence was lower (83%) com-
pared to antiplatelets (94–95%) at each time point.
Multivariable analysis
Antihypertensive, antithrombotic and antilipidemic per-
sistence were examined separately (Table 3). Antihyperg-
lycemic agents were not analyzed due to the low
frequency of use. Factors significantly associated with
antihypertensive nonpersistence were older age, fewer
number of medications prescribed at discharge, and lower
costs of medications at discharge. Nonpersistence was
1.6% in patients 65–79 years old, and 13.8% in patients
80 years and older (p = 0.0003). Patients with monthly
drug costs less than $90.00 per month had a 9.0% non-
persistence rate, while patients with drug costs $200.00BMC Neurology 2008, 8:25 http://www.biomedcentral.com/1471-2377/8/25
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and greater had a 1.4% nonpersistence rate (p = 0.048). In
the multivariable model, age and monthly drug costs were
significant. Patients 65–79 years old had significantly
lower odds of nonpersistence compared to those 80 years
and older (adjusted odds ratio (AOR) 0.11, 95% CI 0.03–
0.39). In addition, patients were significantly more likely
to be nonpersistent with monthly drug costs of < $90 or
$90–199.99, compared to those with costs greater than
$200 (AOR 6.74, 95% CI 1.32–34.46 for < $90; AOR
5.25, 95% CI 1.14–24.25 for $90–199.99).
Factors associated with antithrombotic nonpersistence
were older age, preadmission disability, and disability at
discharge (as measured by OHS score) (Table 3). Nonper-
sistence was 2.1% in patients 65–79 compared to 8.3% in
patients 80 years and older (p = 0.029). Patients depend-
ent on others before admission were also more likely to be
nonpersistent (20.0%) than those who were independent
(4.4%)(p = 0.014). Similarly, patients dependent at dis-
charge were more likely to be nonpersistent than patients
who were independent (10.3% vs 3.5%, respectively) (p =
0.012). Age and preadmission disability were significant
in the multivariable model. Patients between the ages of
65 and 79 years old were significantly less likely to be
nonpersistent than those aged 80 and older (AOR 0.23,
95% CI 0.06–0.81). As well, patients who were disabled
before admission had 7.01 higher odds of nonpersistence
(95% CI 1.66–29.58) than those who were independent.
Characteristics associated with antilipidemic nonpersist-
ence were negative history of previous stroke, and tobacco
use before admission (Table 3). Patients with a history of
previous stroke had a nonpersistence rate of 1.3% com-
pared to 9.1% in those without a history (p = 0.05).
Patients who reported the use of tobacco before their hos-
pital admission had a higher nonpersistence rate (21.7%)
compared to those who did not (6.0%) (p = 0.009). In the
multivariable model only tobacco use was found to be sig-
nificantly associated with antilipidemic nonpersistence
(OR 4.35, 95% CI 1.44–13.13, compared to no tobacco
use).
Discussion
The use of pharmacotherapy for secondary stroke preven-
tion at hospital discharge was extremely common in this
cohort; 96% of patients were prescribed an antithrom-
botic and 91% of patients were prescribed at least one
antihypertensive. The use of antilipidemic therapy was
somewhat less frequent, with 73% prescribed this cate-
gory at discharge. Medication persistence was exception-
ally high with all drug categories exceeding 90% at six
months and 12 months. Persistence was highest for anti-
hyperglycemic drugs (97%) and lowest for antilipidemic
drugs (91%) at one year. Our findings are consistent with
Hamann et al who found that 96% of their stroke patients
were still receiving an antithrombotic medication at one
year.[18] Persistence in the antithrombotic category in
their study was 62% for clopidogrel, 84% for ASA, and
77% for warfarin.[18] Our population had better persist-
ence within this class, with 88% of patients still taking an
antiplatelet agent and 84% an anticoagulant at one year
after stroke. Likewise, Sappok and colleagues found high
medication persistence at one year after stroke for anti-
thrombotics (88%), antihypertensives (91%), and antili-
pidemic therapy (70%).[19]
Medication persistence may be more successful when
pharmacotherapy is initiated during the patient's hospi-
talization, as it was in our cohort. Ovbiagele et al found
Table 1: Characteristics of the 420 Patients Enrolled in the 
Stroke Outcome Study from 2001–2002 at the Queen Elizabeth 
II Health Sciences Centre, Halifax, Nova Scotia, Canada
Characteristic n (%)a
Sex
Male 234 (55.7)
Female 186 (44.3)
Age (years) 68.2 ± 13.8
< 65 138 (32.9)
65–79 198 (47.1)
≥ 80 84 (20.0)
History of previous stroke (n = 418) 109 (26.1)
Length of hospital stay (days) 16.2 ± 21.1
Stroke subtype
Partial anterior circulation 132 (31.4)
Lacunar 106 (25.2)
Posterior circulation 79 (18.8)
Total anterior circulation 30 (7.1)
Transient ischemic attack 59 (14.0)
Uncertain 14 (3.3)
Stroke severity
Transient ischemic attack 35 (8.4)
Mild 90 (21.5)
Moderate 226 (53.9)
Severe 68 (16.2)
Unknown 1 (0.002)
Disability at discharge
Independent 333 (79.3)
Dependent 87 (20.7)
Cognitive impairment at discharge
Not impaired 111 (26.4)
Impaired 84 (20.0)
Missing 225 (53.6)
Atrial fibrillation (n = 418) 60 (14.4)
Average household income (n = 386) $55,472 ± 19,370
Total medications prescribedb 6.4 ± 2.6
Total doses taken per dayb 8.6 ± 4.5
Monthly cost of prescription drugsc $167.10 ± 99.47
aValues expressed as number (%) or mean ± standard deviation, n = 
420 unless otherwise noted
bIncludes all prescription and non-prescription medications ordered 
by a physician at time of discharge
cIncludes only community prescription drug costs at time of discharge 
excluding pharmacist's professional feesBMC Neurology 2008, 8:25 http://www.biomedcentral.com/1471-2377/8/25
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Study Flow Diagram of the 420 Eligible Patients in the Medication Persistence Analysis of the Stroke Outcome Study at the  Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada Figure 1
Study Flow Diagram of the 420 Eligible Patients in the Medication Persistence Analysis of the Stroke Outcome Study at the 
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada.
618 patients enrolled
71 with hemorrhagic stroke
71 died in hospital with ischemic stroke
9 had a missing discharge medication list
467 completed discharge visit with a 
discharge medication list
7 lost to follow-up at 6 months
34 died between discharge and 6 months
1 had a missing 6 month medication list
425 completed 6 month visit with a 6 month 
medication list
5 lost to follow-up at 12 months
420 available for analysis
17 died between 6 and 12 months
1 had a missing 12 month medication list
402 completed 12 month visit with a 12 
month medication listBMC Neurology 2008, 8:25 http://www.biomedcentral.com/1471-2377/8/25
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that patients enrolled in the Stroke PROTECT program in
a California hospital demonstrated high adherence rates
three months after discharge to antithrombotics, statins,
and certain antihypertensives.[20] In addition, Aronow et
al found that starting lipid-lowering therapy in the hospi-
tal after patients underwent coronary angioplasty led to
better long-term adherence in the EPILOG trial.[37] In the
175 patients who started antilipidemic drugs pre-dis-
charge, 77% were persistent at 6 months, compared to
25% of the 1951 patients who started therapy after dis-
charge.[37]
Persistence may also have been positively affected by the
model of care provided by the ASU.[22] Organized stroke
unit care has been found to decrease mortality, and
increase the likelihood of patients functioning independ-
ently and living at home at one year.[38] Follow-up by the
stroke team may also have had unmeasured benefits for
medication persistence. One-third of patients returned for
follow-up visits at the stroke clinic that were unrelated to
the research study, although persistence rates were not sig-
nificantly different among those who returned and those
who did not.
We examined by multivariable analysis the factors associ-
ated with medication persistence. In our study, patients
who did not persist in taking their antihypertensive med-
ications at six months were of older age (80 years and
older), were prescribed fewer medications at discharge,
and had lower drug costs at discharge. Nonpersistence
with antithrombotics was also associated with patients 80
years and older. Older age has not consistently been asso-
ciated with poor persistence, rather it could be that older
persons have more chronic comorbidities and polyphar-
macy, which puts them at risk of stopping their medica-
tions early.[15]
An interesting result was that antihypertensive persistence
was better in patients taking more medications. This may
be related to the fact that patients often need more than
one drug to control their blood pressure, so motivated
patients will be on more medications, and in turn their
persistence will be higher. In a study of heart failure
patients, their adherence to angiotensin-converting
enzyme (ACE) inhibitors and antilipidemic drugs
improved with increasing number of prescription medica-
tions.[39] The authors suggested this could be due to the
Table 2: Medication Use and Persistence by the 420 Patients Enrolled in the Stroke Outcome Study from 2001–2002 at the Queen 
Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
Drug category Users at discharge, 
n (%)
Users at 6 months, 
n (%)
Persistencea at 6 
months (%)
Users at 12 
months, n (%)b
Persistencec at 12 
months (%)b
Antihyperglycemic 104 (24.8) 104 (24.8) 101/104 (97.1) 103 (25.6) 98/101 (97.0)
Insulin 25 (6.0) 26 (6.2) 32 (8.0)
Oral agents 87 (20.7) 86 (20.5) 82 (20.4)
Antihypertensive 384 (91.4) 374 (89.0) 363/384 (94.5) 355 (88.3) 348/367 (94.8)
Diuretic 137 (32.6) 140 (33.3) 151 (37.6)
β-Blocker 182 (43.3) 176 (41.9) 166 (41.3)
CCB 96 (22.9) 102 (24.3) 96 (23.9)
ACE-I 317 (75.5) 291 (69.3) 272 (67.7)
ARB 21 (5.0) 34 (8.1) 40 (10.0)
Other 7 (1.7) 9 (2.1) 10 (2.5)
Antithrombotic 405 (96.4) 392 (93.3) 385/405 (95.1) 379 (94.3) 372/387 (96.1)
Antiplateletd 341 (81.7) 333 (79.3) 322/341 (94.4) 322 (80.1) 310/325 (95.4)
Anticoagulantd 72 (17.1) 71 (16.9) 60/72 (83.3) 69 (17.2) 57/69 (82.6)
Antilipidemic 307 (73.1) 304 (72.4) 285/307 (92.8) 300 (74.6) 276/302 (91.4)
Statin 306 (72.9) 295 (70.2) 293 (72.9)
Other 1 (0.2) 10 (2.4) 9 (2.2)
Combination use
Antihypertensive 
and antithrombotic
373 (88.8) 360 (85.7) 342 (85.1)
Antihypertensive, 
antithrombotic and 
antilipidemic
286 (68.1) 284 (67.6) 274 (68.2)
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker, CCB = calcium channel blocker
aThe percentage of patients persistent at six months is the number of patients still receiving a drug from the drug category at six months divided by 
the total number who were prescribed a drug from the drug category at discharge
bAt 12 months, 17 patients had died and 1 patient had a missing medication list leaving a total of 402 eligible for analysis
cThe percentage of patients persistent at 12 months is the number of patients still receiving a drug from the drug category at 12 months divided by 
the total number who were prescribed a drug from the drug category at discharge and who completed the 12 month visit with a medication list
d8 patients were prescribed both an anticoagulant and an antiplatelet at dischargeB
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Table 3: Characteristics Associated with Medication Nonpersistence at Six Months in the 420 Patients Enrolled in the Stroke Outcome Study from 2001–2002 at the Queen Elizabeth 
II Health Sciences Centre, Halifax, Nova Scotia, Canada
Characteristic Antihypertensive Antithrombotic Antilipidemic
Not Persistenta Unadj OR Adj OR Not Persistenta Unadj OR Adj OR Not Persistenta Unadj OR Adj OR
Stroke Cohort 21/384 (5.5) 20/405 (4.9) 22/307 (7.2)
Age (years)
< 65 7/112 (6.3) 0.42 (0.16, 1.13) 0.37 (0.13, 1.03) 9/130 (6.9) 0.82 (0.29, 2.29) 0.92 (0.32, 2.65) Not significant
65–79 3/192 (1.6) 0.10 (0.03, 0.37) 0.11 (0.03, 0.39) 4/191 (2.1) 0.24 (0.07, 0.83) 0.23 (0.06, 0.81)
≥ 80 11/80 (13.8) 1.00 1.00 7/84 (8.3) 1.00 1.00
Total medications 
prescribedb
0.80 (0.65, 0.995) Not significant Not significant
Monthly drug costsc
< $90.00 7/78 (9.0) 7.05 (1.43, 34.81) 6.74 (1.32, 34.46) Not significant Not significant
$90.00 – $199.99 12/161 (7.5) 5.76 (1.27, 26.18) 5.25 (1.14, 24.25)
≥ $200.00 2/145 (1.4) 1.00 1.00
OHS impairment before 
stroke
Independent Not significant 17/390 (4.4) 1.00 1.00 Not significant
Dependent 3/15 (20.0) 5.49 (1.41, 21.27) 7.01 (1.66, 29.58)
OHS impairment at 
discharge
Independent Not significant 11/318 (3.5) 1.00 Not significant
Dependent 9/87 (10.3) 3.22 (1.29, 8.04)
Tobacco use before 
stroke
Yes Not significant Not significant 5/23 (21.7) 4.35 (1.44, 13.13) 4.35 (1.44, 13.13)
No 17/283 (6.0) 1.00 1.00
History of previous 
stroke
Yes Not significant Not significant 1/76 (1.3) 0.13 (0.02, 1.004)
No 21/230 (9.1) 1.00
Unadj OR = Unadjusted odds ratio (95% confidence interval); Adj OR = adjusted odds ratio (95% confidence interval); OHS = Oxford Handicap Scale
aDefined as not continuing to take a medication in the same drug category from discharge to six months, values expressed as number (%)
bIncludes all prescription and non-prescription medications ordered by a physician at time of discharge
cIncludes only community prescription drug costs at time of discharge excluding pharmacist's professional feesBMC Neurology 2008, 8:25 http://www.biomedcentral.com/1471-2377/8/25
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characteristics of the population such as being highly
motivated by the severity of the illness, compliance with
follow-up visits, and patient beliefs about the need for
medications. As well, increasing medication complexity
may require greater attention to medication-taking.[39] In
a cohort of new statin users enrolled in a US health care
plan, patients were more likely to adhere to their statin
therapy when prescribed more concurrent medica-
tions.[40]
Another aspect of polypharmacy is medication affordabil-
ity. We found that higher monthly medication costs were
associated with greater persistence, so affordability does
not appear to have been a barrier to medication use. One
explanation for this may be that in our cohort, most
patients over the age of 65 would have drug insurance
coverage under the Nova Scotia Senior's Pharmacare Pro-
gram.[41] Seniors pay an annual premium then a copay-
ment for each prescription. Once the maximum
copayment (deductible) is reached, patients do not pay
for additional prescriptions.[41]
Disability at admission and at discharge was significantly
related to nonpersistence with antithrombotic medica-
tions, similar to a finding by Hillen et al where non-treat-
ment with antihypertensives or antithrombotics three
months after stroke was significantly associated with disa-
bility.[17] Sappok et al, however, found disability was not
related to antithrombotic medication compliance in the
multivariable analysis of stroke patients.[19]
An unexpected finding was that antilipidemic nonpersist-
ence was three times higher in patients who used tobacco
before their admission compared to those who did not.
Sappok et al also found that patients with a history of cig-
arette smoking were less persistent with their antithrom-
botic treatment at one year after stroke in the univariate
analysis, but not after adjusting for other factors.[19] Our
results could indicate that tobacco use is associated with
socioeconomic indicators that also affect medication-tak-
ing. The Heart and Stroke Foundation of Canada found
higher rates of tobacco use among Canadians in the low
and medium-low income levels.[42] In a report on the use
of smoking cessation medications after hospitalization for
heart disease, Whelan et al found that there were signifi-
cant socioeconomic differences between patients who did
report the use of these medications, and those who were
still smokers.[43] Patients who still smoked had less pri-
vate drug insurance, had more difficulty paying for basic
needs, and were less nikely to have finished their second-
ary school education.[43] In our sample, it was unknown
how many patients quit smoking after the stroke. It is also
unclear why there is an association between those who
smoked and their antilipidemic medication persistence
and not with persistence in the other drug classes studied.
Further research could help identify the barriers to medi-
cation persistence in people who smoke.
There are limitations to the interpretation of our results.
Reasons for non-persistence were not formally deter-
mined or documented on the medication lists. We have
no data on whether patients stopped taking their medica-
tions because of out of pocket medication costs; although
we attempted to control for this by estimating total
monthly drug costs. Some medications may have been
appropriately discontinued due to contraindications
adverse effects drug interactions lack of efficacy or no
longer needed. The elderly may be more susceptible to the
toxic effects of drugs and were on many medications
which increases the risk of drug interactions. Despite this
the importance of these therapies to reduce further stroke
morbidity and mortality generally means the majority of
patients should be receiving at least one type of medica-
tion from a particular category. Clinical data and lifestyle
changes were not available in this study so the possibility
that some patients reduced their stroke risk and no longer
needed medication can not be ruled out.
We were limited to measuring persistence rather than the
quality of medication taking according to the prescribed
schedule. However persistence is a common useful meas-
urement reported in the literature when other drug use
information is not available. Medication use was self-
reported and was not verified with another source such as
pharmacy administrative claims data. Measuring drug use
can utilize direct methods (eg observation or serum drug
concentrations) or indirect methods (eg self-report phar-
macy refill records)[44]; however a gold standard still
does not exist[15]. Patient self-report is a common
approach used in clinical settings[44] and has been found
to have good concordance (80% 85% and 91%) with
pharmacy claims data in studies of antidepressant and car-
diovascular medication use [45-47]. Misclassification
error in drug use could have occurred if patients were inac-
curate with their self-reported medication lists despite
attempts by the study coordinator to be as thorough as
possible when collecting the data at six and 12 months.
Finally the number of patients who were nonpersistent in
each drug category was small and variable which resulted
in wide confidence intervals and a less precise estimate of
effect in the multivariable analysis.
Conclusion
Self-reported medication persistence rates were high
among this cohort of stroke patients enrolled in a pro-
spective study at the Acute Stroke Unit of the QEII HSC in
Halifax, Nova Scotia. Physicians, pharmacists and other
healthcare providers caring for patients after stroke should
recognize factors potentially associated with nonpersist-
ence such as older age fewer prescribed medications disa-BMC Neurology 2008, 8:25 http://www.biomedcentral.com/1471-2377/8/25
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bility before and after stroke and previous tobacco use in
order to counsel and support patients at risk. The relation-
ships between medication persistence tobacco use and
drug costs need further clarification. Improving medica-
tion persistence may improve outcomes after stroke and
reduce the burden of disease on the healthcare system.
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